SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is drawing attention amid a recent rebound and hopes for a technical breakout, with traders pointing to AI-server demand, customer partnerships and the upcoming earnings report as potential supports. Bulls are speculating about a short squeeze and valuation recovery, while skeptics cite inconsistent momentum and ongoing dilution, financing and execution concerns.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound and push toward a breakout from its recent consolidation are driving attention, with traders pointing to bullish momentum and possible short covering. Optimists expect the advance to continue, while skeptics warn of repeated resistance and another pullback.

Stablecoin Development Corp. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in West Palm Beach, FL.

Stablecoin Development Corp.

SDEVs sharp, high-volume rally is driving momentum-trading chatter, with many traders speculating about a low-float short squeeze and pointing to gains in SKY, the token held in the companys treasury. Others question the moves fundamental support, noting there is no confirmed new business catalyst and warning that potential share dilution and a sharp reversal could weigh on the stock.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Three successful launches in under 13 hours, including a Google/Planet Labs orbital AI-chip test, fueled attention alongside optimism about SpaceXs AI-computing business. Bulls celebrated the breakout and speculated about a short squeeze, while skeptics raised valuation concerns and warned that upcoming share unlocks could add selling pressure.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs sharp, high-volume rally and close above a key price level have fueled speculation about what is driving the move. Much of the discussion centers on Michael Caputos appointment to the Presidents Cancer Panel and his public exchange with ImmunityBio founder Patrick Soon-Shiong, though traders debate whether that, anticipated ANKTIVA catalysts, institutional buying, or short covering explains the price action; squeeze expectations are widespread but unconfirmed.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings denial that it is pursuing a Monzo acquisition has fueled a rebound after acquisition reports pressured the shares. Traders largely view the clarification as relief and point to buyers returning, though some remain skeptical of the recovery and continue debating the companys expansion strategy.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

A reported, not-yet-finalized federal loan to support upgrades at Vistras nuclear plants is drawing attention, with traders linking the potential capacity growth to rising AI and data-center electricity demand. Many view the report as bullish, while others point to the stocks choppy price action and question why the news has not produced a sustained move higher.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

FETs sharp rebound and relative strength are drawing attention amid renewed interest in AI-agent crypto tokens; traders point to Fetch.ai/ASI product developments and partnership claims, though these are discussed as catalysts rather than uniformly verified news. The reaction is largely bullish, with dip-buying and breakout hopes competing with concerns about resistance, past underperformance, and Bitcoins influence on altcoins.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention for technology-sector strength and reports of fresh all-time highs, with traders pointing to mega-cap tech and AI-related stocks as key drivers. Some welcome the breakout, while others warn that leadership is narrow and weak market breadth means gains may not reflect broad-based strength.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials strong quarterly results and upbeat outlook have fueled debate after shares initially sold off, with traders saying lofty expectations and concerns about growth and margins overshadowed AI-driven semiconductor equipment demand. The community remains split between buying the pullback on long-term capex optimism and cautioning that valuation and sector volatility could keep shares under pressure.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$OCUL I strongly believe there are likely informal &amp; confidential strategic discussions ongoing as we speak for Ocul. Everyone is waiting for the NDA submission to put things together for an offer. 
 
 Pravin Dugel last Buyout timeline of Ivirec in 2023, as an example of his experience and how quickly things escalate: 
 
December 2022: NDA submission of new drug 
 
January 2023: Initial informal &amp; confidential discussions of buyout with Astellasakes 
 
March 31, 2023: Astellasakes  formal cash offer  
 
Mid-April 2023: Competitors like Bayer submitted alternative bids 
 
April 27, 2023: Astellas raised its buyout offer 
 
April 30, 2023: The companies officially announced agreement  
 
July 11, 2023: Astellas completed the acquisition.  and Ivirec stock was delisted 
 
August 2023: FDA approval of new drug

Max klimovich

Holy

Aaron Pell

hi ki

Andy Durham

Steve

StockTwits Web

Ocular Therapeutix Inc

 I strongly believe there are likely informal & confidential strategic discussions ongoing as we speak for Ocul. Everyone is waiting for the NDA submission to put things together for an offer. 
 
 Pravin Dugel last Buyout timeline of Ivirec in 2023, as an example of his experience and how quickly things escalate: 
 
December 2022: NDA submission of new drug 
 
January 2023: Initial informal & confidential discussions of buyout with Astellasakes 
 
March 31, 2023: Astellasakes  formal cash offer  
 
Mid-April 2023: Competitors like Bayer submitted alternative bids 
 
April 27, 2023: Astellas raised its buyout offer 
 
April 30, 2023: The companies officially announced agreement  
 
July 11, 2023: Astellas completed the acquisition.  and Ivirec stock was delisted 
 
August 2023: FDA approval of new drug

Chris H

@Appulen  This is not the time to maximize value.   (Go see if you can find Pravin’s statements from last year about the timing of buyouts).  Sorry, this one needs more patience.

StockTwits for iOS

  This is not the time to maximize value.   (Go see if you can find Pravin’s statements from last year about the timing of buyouts).  Sorry, this one needs more patience.

@Goodstockday The AXPAXLI TKI molecule is a completely new therapy in the market. It will be the first to market ever. I believe big pharma would like the honours of being first to market with this new drug. Big pharma will not wait for two-three years down the road to gobble Ocul at its full price.  
 
Most &quot;one trick pony&#39;s&quot; are sold before they hit the market. I believe Ocul is designed for a buyout, however, Ocul is ready to go at it alone if necessary. 
 
If Sonofi interest last year was genuine, which I believe it was, big pharma are ready to make a bid, especially when the label becomes known during the NDA process. I believe the label is the last piece of the valuation equation which needs to be known fo a complete future valuation thesis. 
 
In just a few months, it will become quite evident with a large degree of confidence how much this company is worth.

Josh D.

 The AXPAXLI TKI molecule is a completely new therapy in the market. It will be the first to market ever. I believe big pharma would like the honours of being first to market with this new drug. Big pharma will not wait for two-three years down the road to gobble Ocul at its full price.  
 
Most "one trick pony's" are sold before they hit the market. I believe Ocul is designed for a buyout, however, Ocul is ready to go at it alone if necessary. 
 
If Sonofi interest last year was genuine, which I believe it was, big pharma are ready to make a bid, especially when the label becomes known during the NDA process. I believe the label is the last piece of the valuation equation which needs to be known fo a complete future valuation thesis. 
 
In just a few months, it will become quite evident with a large degree of confidence how much this company is worth.

@Appulen @Goodstockday with kod getting ready to possibly displace vabysmo and eyelea or seriously cut into revenue , i would have to believe one of them would be stepping up to buyout ocular out

StockTwits For Android 

 with kod getting ready to possibly displace vabysmo and eyelea or seriously cut into revenue , i would have to believe one of them would be stepping up to buyout ocular out

@highkick my impression is Kod/Zenkuda is not an effective drug. It failed the first trials back in 2022. This time around they added a 4th loading dose, there is no data how this drug is effective with just one redose injection. We just have to use our imagination I guess. 
 
The anti-VEGF molecule they use simply doesn&#39;t cut it IMHO. They have a subpar drug to Eylea and Vabysmo. The stock price was pumped by an internal shareholder. Noone to my knowledge has stepped up to buy a relevant number of Kod shares other than the biggest existing shareholder.

 my impression is Kod/Zenkuda is not an effective drug. It failed the first trials back in 2022. This time around they added a 4th loading dose, there is no data how this drug is effective with just one redose injection. We just have to use our imagination I guess. 
 
The anti-VEGF molecule they use simply doesn't cut it IMHO. They have a subpar drug to Eylea and Vabysmo. The stock price was pumped by an internal shareholder. Noone to my knowledge has stepped up to buy a relevant number of Kod shares other than the biggest existing shareholder.